UroGen Pharma’s Chairman, Arie Belldegrun, MD, FACS to Receive EY 2018 Master Entrepreneur Award
The Master Entrepreneur Award is an exclusive designation by the Ernst & Young Entrepreneur of the Year judging panel bestowed upon an individual who distinctly outperforms the customary characteristics of an entrepreneur, exemplifies leadership at its best, drives a successful business or brand with notable longevity and greatly contributes to the local economy and community.
“We congratulate Arie on this well-deserved honor,” said
“With a unique perspective of surgeon, researcher and entrepreneur, Arie has led a revolution that brought an entirely new type of medicine to the market while overcoming scientific and commercial challenges,” said
Dr. Belldegrun is the Chairman of UroGen. He has a distinguished career as a visionary surgeon, scientist and life sciences entrepreneur. Dr. Belldegrun founded Kite Pharma, a biopharmaceutical company engaged in the development of innovative cancer immunotherapies where he served as Chairman, President, and Chief Executive Officer until the acquisition of Kite by
Dr. Belldegrun is a Professor of Urology, holds the Roy and Carol Doumani Chair in Urologic Oncology, and is Director of the
Prior to joining
For more information on the EY Entrepreneur of the Year Awards, please visit ey.com/eoy.
About UroGen Pharma Ltd.
This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including with respect to the timing and results of clinical development and commercial prospects of the product candidates in UroGen’s pipeline, including UGN-101 (MitoGel™), and the ability of UroGen to become a leader in the field of uro-oncology, particularly in the treatment of low-grade UTUC, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to: the potential approval of its first therapy; the ability to obtain and maintain regulatory approval; the scope, progress and expansion of developing and commercializing UroGen’s product candidates; and UroGen’s ability to attract or retain key management and personnel. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section of our annual report for the year ended December 31, 2017 filed with the SEC on March 15, 2018 and other filings that UroGen makes with the SEC from time to time (which are available at http://www.sec.gov), the events and circumstances discussed in such forward-looking statements may not occur, and UroGen’s actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date of this press release and are based on information available to UroGen as of the date of this release.